Table 3.
Trends over time (Days 4–32)
| Group | Day | Group * Day | |||||||
|---|---|---|---|---|---|---|---|---|---|
| F | Df | p | F | Df | p | F | df | P | |
| Primary outcome | |||||||||
| HAM-D-6 | 1.03 | (2, 81) | 0.36 | 3.1 | (1, 81) | 0.08 | 0.19 | (2, 81) | 0.83 |
| Secondary outcomes | |||||||||
| MADRS | 0.72 | (2, 81) | 0.49 | 0.6 | (1, 81) | 0.44 | 0.45 | (2, 81) | 0.64 |
| SDQ | 0.66 | (2, 81) | 0.52 | 4.75 | (1, 81) | 0.03* | 0.75 | (2, 81) | 0.47 |
| CPFQ | 0.47 | (2, 81) | 0.63 | 7.04 | (1, 81) | 0.01** | 0.55 | (2, 81) | 0.58 |
| VAS3-sad | 0.84 | (2, 81) | 0.44 | 2.15 | (1, 81) | 0.15 | 0.79 | (2, 81) | 0.46 |
Note: Group refers to the treatment arm randomization (A:A:A:A vs. S:S:A:A vs. S:S:S:S); Day refers to study day, modeled continuously (days 4–32)